DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,708,037 | +19.3% | 23,007 | +15.4% | 1.40% | +25.3% |
| Q2 2023 | $4,784,400 | -8.0% | 19,935 | -3.3% | 1.12% | -11.6% |
| Q1 2023 | $5,198,073 | -5.9% | 20,624 | -0.9% | 1.26% | -10.5% |
| Q4 2022 | $5,521,532 | +2.9% | 20,803 | +0.1% | 1.41% | -1.9% |
| Q3 2022 | $5,366,000 | +5.5% | 20,777 | +3.6% | 1.44% | +3.2% |
| Q2 2022 | $5,086,000 | -51.9% | 20,060 | -44.4% | 1.40% | -44.4% |
| Q1 2022 | $10,576,000 | -16.2% | 36,056 | -5.9% | 2.51% | -10.5% |
| Q4 2021 | $12,613,000 | +24.2% | 38,337 | +14.9% | 2.81% | +14.8% |
| Q3 2021 | $10,157,000 | -12.4% | 33,364 | -22.8% | 2.45% | -13.4% |
| Q2 2021 | $11,592,000 | +21.5% | 43,196 | +1.9% | 2.82% | +7.3% |
| Q1 2021 | $9,541,000 | +16.1% | 42,389 | +14.5% | 2.63% | +5.3% |
| Q4 2020 | $8,221,000 | -35.4% | 37,009 | -37.4% | 2.50% | -41.2% |
| Q3 2020 | $12,724,000 | +18.8% | 59,093 | -2.4% | 4.24% | +10.4% |
| Q2 2020 | $10,707,000 | +25.8% | 60,552 | -1.5% | 3.84% | -5.2% |
| Q1 2020 | $8,512,000 | -13.7% | 61,496 | -4.3% | 4.05% | +44.6% |
| Q4 2019 | $9,860,000 | +2.1% | 64,244 | -4.0% | 2.80% | -2.4% |
| Q3 2019 | $9,661,000 | -3.1% | 66,893 | -4.2% | 2.87% | +4.6% |
| Q2 2019 | $9,975,000 | +6.0% | 69,795 | -2.1% | 2.74% | +6.5% |
| Q1 2019 | $9,410,000 | +17.5% | 71,280 | -8.2% | 2.58% | -9.4% |
| Q4 2018 | $8,011,000 | -4.7% | 77,684 | +0.4% | 2.84% | +25.8% |
| Q3 2018 | $8,404,000 | +14.9% | 77,343 | +4.4% | 2.26% | +8.1% |
| Q2 2018 | $7,312,000 | +2.2% | 74,100 | +1.4% | 2.09% | -6.5% |
| Q1 2018 | $7,158,000 | -5.1% | 73,107 | -10.0% | 2.24% | +12.7% |
| Q4 2017 | $7,540,000 | +7.9% | 81,236 | -0.3% | 1.98% | +4.4% |
| Q3 2017 | $6,990,000 | +1.3% | 81,491 | -0.3% | 1.90% | -0.7% |
| Q2 2017 | $6,899,000 | -2.6% | 81,756 | -1.2% | 1.92% | -2.9% |
| Q1 2017 | $7,081,000 | +10.3% | 82,788 | +0.3% | 1.97% | +6.9% |
| Q4 2016 | $6,422,000 | +4.0% | 82,504 | +4.7% | 1.84% | +4.0% |
| Q3 2016 | $6,174,000 | -17.1% | 78,764 | +6.8% | 1.77% | -22.4% |
| Q2 2016 | $7,447,000 | +1.0% | 73,729 | -5.2% | 2.29% | -2.4% |
| Q1 2016 | $7,375,000 | +0.2% | 77,742 | -1.9% | 2.34% | +3.9% |
| Q4 2015 | $7,360,000 | +1.4% | 79,237 | -6.9% | 2.26% | +5.3% |
| Q3 2015 | $7,255,000 | -8.1% | 85,147 | -7.7% | 2.14% | +17.7% |
| Q2 2015 | $7,896,000 | +1.3% | 92,252 | +0.5% | 1.82% | +4.2% |
| Q1 2015 | $7,792,000 | -21.2% | 91,775 | -20.5% | 1.75% | -23.0% |
| Q4 2014 | $9,891,000 | +13.2% | 115,397 | +0.3% | 2.27% | +20.9% |
| Q3 2014 | $8,738,000 | +2.1% | 115,007 | +5.8% | 1.88% | -3.4% |
| Q2 2014 | $8,557,000 | -0.1% | 108,683 | -4.8% | 1.94% | -11.7% |
| Q1 2014 | $8,566,000 | -41.0% | 114,208 | -39.3% | 2.20% | -5.9% |
| Q4 2013 | $14,517,000 | +12.0% | 188,041 | +0.5% | 2.34% | +2.8% |
| Q3 2013 | $12,965,000 | +9.6% | 187,034 | +0.1% | 2.28% | +1.1% |
| Q2 2013 | $11,830,000 | – | 186,893 | – | 2.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |